| 王大榛,张正凤,杨 柳,等.晚期肝细胞癌的系统治疗现状及研究进展[J].肿瘤学杂志,2023,29(12):1060-1068. |
| 晚期肝细胞癌的系统治疗现状及研究进展 |
| Current Status and Progress of Systemic Therapy for Advanced Hepatocellular Carcinoma |
| 投稿时间：2023-03-07 |
| DOI：10.11735/j.issn.1671-170X.2023.12.B011 |
|
 |
| 中文关键词: 肝细胞癌 分子靶向治疗 免疫治疗 病因治疗 新靶点 |
| 英文关键词:hepatocellular carcinoma molecular targeted therapy immunotherapy etiology therapy new targets |
| 基金项目:北京医学奖励基金会（YXJL-2022-0080-0015）； 哈尔滨医科大学附属肿瘤医院海燕科研基金（JJZD2020-03） |
|
| 摘要点击次数: 254 |
| 全文下载次数: 150 |
| 中文摘要: |
| 摘 要：肝细胞癌（hepatocellular carcinoma，HCC），是一种发病率和死亡率高、预后差且易复发和转移的消化系统恶性肿瘤。以靶向治疗和免疫治疗为主的系统治疗在晚期HCC一线治疗中疗效肯定。靶向治疗联合免疫治疗可有效延长患者生存期，改善预后，中药辅助治疗也在综合抗肿瘤治疗中发挥作用。病因治疗和新的抗HCC作用靶点也是肝细胞癌领域的研究热点。全文主要围绕晚期HCC的靶向治疗、免疫治疗等系统治疗以及病因和新作用靶点研究的现状及进展进行综述。 |
| 英文摘要: |
| Abstract： Hepatocellular carcinoma（HCC） is a malignant tumor of the digestive system with high morbidity and mortality， poor prognosis， and a tendency of recurrence and metastasis. The efficacy of targeted and immune-based systemic therapy as the first-line treatment for advanced HCC has been confirmed. Targeted therapy combined with immunotherapy is effective in prolonging survival and improving prognosis of patients， while adjuvant Chinese medicine may also play a role in comprehensive anti-tumor treatment. Etiological treatment and new targets are also hot research topics in the field of HCC. This paper reviews the current status and recent advances in the research of targeted and immune-based systemic therapies for advanced HCC as well as etiology and new targets of action. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |